{"organizations": [], "uuid": "ed12c1f9a89187dbe6055c34dc79681169c9bbc2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-implement/brief-ironwood-pharmaceuticals-implements-reduction-in-field-based-workforce-idUSFWN1PP19C", "country": "US", "domain_rank": 408, "title": "BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-30T20:37:00.000+02:00", "replies_count": 0, "uuid": "ed12c1f9a89187dbe6055c34dc79681169c9bbc2"}, "author": "", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-implement/brief-ironwood-pharmaceuticals-implements-reduction-in-field-based-workforce-idUSFWN1PP19C", "ord_in_thread": 0, "title": "BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sec", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ironwood pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Ironwood Pharmaceuticals Inc:\n* SAYS ‍COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT​\n* SAYS COMMENCED IMPLEMENTATION OF A REDUCTION IN ITS FIELD-BASED WORKFORCE & WILL BE DECREASING IT BY APPROXIMATELY 60 EMPLOYEES\n* SAYS ‍ESTIMATES IT WILL INCUR AGGREGATE CHARGES RELATED TO REDUCTION IN FIELD-BASED WORKFORCE OF ABOUT $2.3 MILLION TO $2.8 MILLION​\n* SAYS ‍EXPECTS TO COMPLETE REDUCTION IN ITS FIELD-BASED WORKFORCE DURING Q1 OF 2018​\n* SAYS INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR ITS LESINURAD FRANCHISE INCLUDES DUZALLO AND ZURAMPIC - SEC FILING Source text: ( bit.ly/2nuOpuO ) Further company coverage:\n ", "external_links": [], "published": "2018-01-30T20:37:00.000+02:00", "crawled": "2018-01-30T20:58:07.006+02:00", "highlightTitle": ""}